Medicare To Cover Drugs That May Slow Alzheimer’s

Coverage could begin immediately after these drugs win traditional approval from the FDA, CMS says.

By Rethinking65

Medicare will cover drugs that may slow the progression of Alzheimer’s disease if the FDA grants these drugs traditional approval, the Centers for Medicare & Medicaid Services (CMS) recently announced.

To be eligible for coverage, people must be enrolled in Medicare Part B, diagnosed with mild cognitive impairment or early dementia caused by Alzheimer’s disease, and receiving treatment and follow-up care from qualified medical providers, CMS said in its release. A patient’s physician and clinical team are required to participate in a registry that collects evidence about how effectively these drugs work with Medicare patients in the real world.

More than 6 million Americans are living with Alzheimer’s.

The FDA has not yet given traditional approval to any drugs used to slow the progression of Alzheimer’s although it did grant accelerated approval to two such drugs. The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee is scheduled on June 9 to discuss the results of a confirmatory trial of one of those drugs, Leqembi. A potential decision on traditional approval of the drug is possible within weeks, noted CMS.

“Broader Medicare coverage would begin on the same day the FDA grants traditional approval,” CMS also stated.

Targeting brain buildup and data breaches

According to Stanford Medicine, Leqembi and the other drug granted accelerated FDA approval, Aduhelm, target removal of brain amyloid. Amyloid is one of the proteins that build up in brain in people with Alzheimer’s.

“Alzheimer’s disease takes a toll on not just the people suffering from the disease but also on their loved ones and caregivers in a way that almost no other illness does. CMS has always been committed to helping people obtain timely access to innovative treatments that meaningfully improve care and outcomes for this disease,” CMS Administrator Chiquita Brooks-LaSure Brooks-LaSure said in the statement. “I hope we see more private sector partners in this work making their own announcements soon.”

CMS is making efforts to address data security concerns for drug registries. A CMS-facilitated portal will collect information for the registry in an easy-to-use format once an Alzheimer’s drug wins traditional approval. According to CMS, the portal will adhere to robust privacy protections in accordance with federal laws and regulations, including HIPAA. CMS is also working with multiple organizations that are preparing to open their own registries.


Latest news

Advisors Dabbling in DC Market Seek Greater Support: Cerulli

Providing them with tools, education and guidance would help them grow their retirement-plan businesses, says Cerulli Associates.

Executives Traveling on Corporate Jets Face IRS Scrutiny

Do you have executive clients who might be using a corporate jet for personal use? Tell them the IRS has announced a crackdown.

U.S. Solo Renters Age 50+ Way Up

The number living alone rose by more than half a million, but there’s been a growing trend of older people living with roommates.

SEC Settles Charges Against Former Advisor

The former advisor, Andrew Komarow, was known in the industry for working with special needs families and neurodivergent clients.

SEC Fines TIAA Unit $2.2M for Violating Reg BI

The SEC said a TIAA broker-dealer charged some retail customers too much to invest in mutual-fund choices in an IRA.

Even Millionaires Flunk Retirement 101: Study

The American College of Financial Services plans to use its new research to help advisors improve client conversations.